Triple combination therapy in patients infected with COVID-19
JPRN; 27/02/2020; TrialID: JPRN-jRCTs031190227
Clinical Trial Register
| ICTRP | ID: ictrp-JPRN-jRCTs031190227
ABSTRACT
Condition
patients infected with COVID-19Coronavirus;Coronavirus
Intervention
oral administration of lopinavir, ritonavir and hydroxychloroquine with or without oseltamivirPrimary outcome:
expected value and 95% CI of ratio of C-reactive protein before versus after the treatmentCriteria
Inclusion criteria positive result for COVID-19 detection testfever above 37.5 degree Celsius, or pneumonia shadow on chest X-ray or CT-scan
hospital admission
Exclusion criteria past history of hypersensitivity to lopinavir, ritonavir, hydroxychloroquine or oseltamivir
pregnancy
Collection:
Clinical trial registers
Database:
ICTRP
Year:
2020
Document Type:
Clinical Trial Register
Similar
MEDLINE
...
LILACS
LIS